Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Oppenheimer initiates coverage on Climb Bio stock with outperform rating | 1 | Investing.com | ||
Fr | Oppenheimer beginnt Berichterstattung über Climb Bio-Aktie mit Outperform-Rating | 1 | Investing.com Deutsch | ||
CLIMB BIO Aktie jetzt für 0€ handeln | |||||
Do | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Mi | Clym: ARD Money Maker portraitiert Solarpunk-Macher Clym | 1 | GamesWirtschaft | ||
22.05. | BTIG sets Climb Bio stock Buy rating, $7 target | 2 | Investing.com | ||
19.05. | Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 91 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,... ► Artikel lesen | |
14.05. | Climb Bio GAAP EPS of -$0.31 | 1 | Seeking Alpha | ||
14.05. | Climb Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
14.05. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
25.03. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates | 556 | GlobeNewswire (Europe) | Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus... ► Artikel lesen | |
25.03. | Climb Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
24.02. | Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer | 356 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished... ► Artikel lesen | |
10.01. | Climb Bio enters licensing deal with Mabworks for CLYM116 development | 1 | Pharmaceutical Technology | ||
10.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.01. | Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy | 227 | GlobeNewswire (Europe) | Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically... ► Artikel lesen | |
19.12.24 | Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index | 134 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)... ► Artikel lesen | |
24.10.24 | Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations | 314 | ACCESS Newswire | Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE... ► Artikel lesen | |
02.10.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. | 187 | GlobeNewswire (Europe) | Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Unbedingt beachten wegen Montag! | ||
MODERNA | 23,805 | +1,08 % | Kurs von Moderna steigt etwas (24,09 €) | Im US-amerikanischen Wertpapierhandel liegt das Wertpapier von Moderna gegenwärtig im Plus. Die Aktie notiert aktuell bei 24,09 Euro. Die Aktie von Moderna verzeichnet zur Stunde ein Kursplus von 4... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 434,60 | +0,44 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform |